Gilead Sciences

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
BioSpace
Thu, 12/19/24 - 11:27 am
Gilead Sciences
Assembly Bio
funding
hepatitis D
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
Fierce Pharma
Thu, 12/12/24 - 11:44 pm
ICER
drug pricing
Gilead Sciences
JNJ
Novartis
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wed, 12/11/24 - 11:40 am
Gilead Sciences
Biktarvy
patent cliffs
HIV
Can CAR-T first movers keep pace in a rapidly evolving market?
Pharmaphorum
Wed, 12/11/24 - 10:59 am
CAR-T
Gilead Sciences
Novartis
Gilead/Arcellx’s anito-cel’s differentiated safety profile challenges J&J/Legend’s Carvykti
BioSpace
Tue, 12/10/24 - 11:41 am
Gilead Sciences
Arcellx
anito-cel
JNJ
Carvykti
Multiple Myeloma
Gilead looks beyond Trodelvy with Tubulis alliance
Pharmaphorum
Tue, 12/3/24 - 09:41 am
Gilead Sciences
Tubulis
antibody-drug conjugates
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Clinical Trials Arena
Sun, 12/1/24 - 11:46 am
Gilead Sciences
clinical trials
lenacapavir
HIV
PrEP
Gilead’s Livdelzi shows promise in PBC clinical trial
Clinical Trials Arena
Mon, 11/18/24 - 11:08 am
Gilead Sciences
Livdelzi
primary biliary cholangitis
clinical trials
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Fierce Biotech
Thu, 11/14/24 - 11:08 pm
Gilead Sciences
Seattle
R&D
layoffs
Autolus enters CAR-T race with FDA approval for Aucatzyl
Fierce Pharma
Mon, 11/11/24 - 11:49 am
Autolus Therapeutics
CAR-T
FDA
Aucatzyl
Gilead Sciences
Novartis
relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Fierce Pharma
Thu, 11/7/24 - 11:29 am
Gilead Sciences
earnings
Trodelvy
CAR-T
Gilead, Merck say HIV combo could be weekly, oral HIV drug
Pharmaphorum
Mon, 10/21/24 - 09:35 am
Gilead Sciences
Merck
HIV
antiretrovirals
clinical trials
islatravir
Sunleca
Gilead withdraws bladder cancer drug in US after failed trial
Reuters
Fri, 10/18/24 - 11:35 am
Gilead Sciences
Trodelvy
bladder cancer
clinical trials
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
Fierce Pharma
Thu, 10/17/24 - 09:23 am
GSK
Gilead Sciences
PrEP
HIV
Apretude
Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data
Fierce Biotech
Fri, 10/11/24 - 11:14 am
Gilead Sciences
Yuhan
MASH
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Reuters
Wed, 10/2/24 - 09:55 pm
Gilead Sciences
generics
HIV
lenacapavir
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Fierce Pharma
Thu, 09/19/24 - 09:22 pm
Gilead Sciences
Kite Pharma
China
Fosun Kite Biotechnology
Fosun Pharma
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
BioPharma Dive
Mon, 09/16/24 - 10:14 pm
Kyverna Therapeutics
Gilead Sciences
Kite Pharma
CAR-T
cell therapy
Gilead’s twice-yearly shot cut HIV infections by 96% in trial
CNBC
Thu, 09/12/24 - 10:28 am
Gilead Sciences
HIV
lenacapavir
Gilead's Trodelvy triplet underwhelms, but bolsters company's phase 3 lung cancer design
Fierce Pharma
Mon, 09/9/24 - 07:12 pm
Gilead Sciences
Trodelvy
non-small cell lung cancer

Pages